Werewolf Therapeutics Stock Probability of Future Stock Price Finishing Over 0.67
| HOWL Stock | USD 0.67 0.05 6.94% |
Closest to current price Werewolf long PUT Option Payoff at Expiration
Werewolf Therapeutics Target Price Odds to finish over 0.67
The tendency of Werewolf Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.67 | 90 days | 0.67 | about 74.22 |
Based on a normal probability distribution, the odds of Werewolf Therapeutics to move above the current price in 90 days from now is about 74.22 (This Werewolf Therapeutics probability density function shows the probability of Werewolf Stock to fall within a particular range of prices over 90 days) .
Werewolf Therapeutics Price Density |
| Price |
Predictive Modules for Werewolf Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Werewolf Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Werewolf Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Werewolf Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Werewolf Therapeutics is not an exception. The market had few large corrections towards the Werewolf Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Werewolf Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Werewolf Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.74 | |
β | Beta against Dow Jones | 1.62 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | -0.09 |
Werewolf Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Werewolf Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Werewolf Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
Werewolf Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Werewolf Stock often depends not only on the future outlook of the current and potential Werewolf Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Werewolf Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 43.9 M | |
| Cash And Short Term Investments | 111 M |
Werewolf Therapeutics Technical Analysis
Werewolf Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Werewolf Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Werewolf Therapeutics. In general, you should focus on analyzing Werewolf Stock price patterns and their correlations with different microeconomic environments and drivers.
Werewolf Therapeutics Predictive Forecast Models
Werewolf Therapeutics' time-series forecasting models is one of many Werewolf Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Werewolf Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Werewolf Therapeutics
Checking the ongoing alerts about Werewolf Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Werewolf Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics has some characteristics of a very speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Insider Selling Werewolf Therapeutics Director Sells 20,942.28 in Stock |
Check out Werewolf Therapeutics Analysis, Werewolf Therapeutics Valuation, Werewolf Therapeutics Correlation, Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Volatility, Werewolf Therapeutics Price History as well as Werewolf Therapeutics Performance. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.